A Phase 3 interventional study of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) and 7-Valent Pneumococcal Conjugate Vaccine (7vPnc) in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 4 sites in Brazil. Open to participants aged 28 Days to 54 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-08.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy infants in Brazil for safety and tolerability, and to determine the immune response to the vaccines.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
Biological: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
Biological: 7-Valent Pneumococcal Conjugate Vaccine (7vPnc)
Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: 1 Month after the infant series (7 Months of age)
Percentage of Participants Achieving Antibody Level ≥5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
Percentage of participants achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.
Time frame: 1 month after the infant series (7 months of age)
Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose
Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: 1 month after the toddler dose (13 months of age)
Percentage of Participants Achieving Antibody Level ≥5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose
Percentage of participants achieving predefined antibody threshold ≥5 EU/mL along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.
Time frame: 1 month after the toddler dose (13 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 1 (2 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 2 (4 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 3 (6 months of age)
Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 4 days after toddler dose (12 months of age)
Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 1 (2 months of age)
Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 2 (4 months of age)
Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after dose 3 (6 months of age)
Percentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 4 days after toddler dose (12 months of age)
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 177 | 177 |
| Vaccinated dose 1 | 163 | 162 |
| Vaccinated dose 2 | 159 | 162 |
| Vaccinated dose 3 | 158 | 161 |
| Completed | 157 | 159 |
| Not completed | 20 | 18 |
| Withdrew: Parent or legal guardian request | 10 | 8 |
| Withdrew: Protocol violation | 6 | 3 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Failed to return | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Died prior to receiving 7vpnc | 0 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 157 | 159 |
| Completed | 156 | 156 |
| Not completed | 1 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Failed to return | 1 | 1 |
| Milestone | 13vPnC | 7vPnC |
|---|---|---|
| Started | 156 | 156 |
| Completed | 153 | 156 |
| Not completed | 3 | 0 |
| Withdrew: Failed to return | 2 | 0 |
| Withdrew: Parent or legal guardian request | 1 | 0 |
Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Common serotypes - serotype 4 | 100.0 (97.7 to 100.0) | 100.0 (97.7 to 100.0) |
| Common serotypes - serotype 6B | 96.8 (92.7 to 99.0) | 95.6 (91.1 to 98.2) |
| Common serotypes - serotype 9V | 98.7 (95.4 to 99.8) | 100.0 (97.7 to 100.0) |
| Common serotypes - serotype 14 | 98.1 (94.5 to 99.6) | 97.5 (93.6 to 99.3) |
| Common serotypes - serotype 18C | 97.4 (93.6 to 99.3) | 98.1 (94.5 to 99.6) |
| Common serotypes - serotype 19F | 94.2 (89.3 to 97.3) | 98.7 (95.5 to 99.8) |
| Common serotypes - serotype 23F | 96.8 (92.7 to 99.0) | 93.0 (87.8 to 96.5) |
| Additional serotypes - serotype 1 | 99.4 (96.5 to 100.0) | 2.5 (0.7 to 6.4) |
| Additional serotypes - serotype 3 | 87.1 (80.8 to 91.9) | 4.4 (1.8 to 8.9) |
| Additional serotypes - serotype 5 | 98.7 (95.4 to 99.8) | 38.2 (30.4 to 46.4) |
| Additional serotypes - serotype 6A | 97.4 (93.6 to 99.3) | 52.6 (44.4 to 60.6) |
| Additional serotypes - serotype 7F | 100.0 (97.7 to 100.0) | 1.3 (0.2 to 4.6) |
| Additional serotypes - serotype 19A | 99.4 (96.5 to 100.0) | 98.7 (95.4 to 99.8) |
Percentage of participants achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| PT ≥5 EU/mL | 35.9 (28.4 to 44.0) | 32.3 (25.1 to 40.2) |
| FHA ≥5 EU/mL | 70.1 (62.2 to 77.2) | 71.5 (63.8 to 78.4) |
| PRN ≥5 EU/mL | 93.5 (88.5 to 96.9) | 96.2 (91.9 to 98.6) |
Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Common serotypes - serotype 4 | 100.0 (97.6 to 100.0) | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 6B | 97.4 (93.4 to 99.3) | 98.7 (95.3 to 99.8) |
| Common serotypes - serotype 9V | 100.0 (97.6 to 100.0) | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 14 | 100.0 (97.6 to 100.0) | 99.3 (96.4 to 100.0) |
| Common serotypes - serotype 18C | 99.3 (96.4 to 100.0) | 100.0 (97.6 to 100.0) |
| Common serotypes - serotype 19F | 99.3 (96.4 to 100.0) | 98.7 (95.3 to 99.8) |
| Common serotypes - serotype 23F | 98.7 (95.3 to 99.8) | 99.3 (96.4 to 100.0) |
| Additional serotypes - serotype 1 | 100.0 (97.6 to 100.0) | 2.7 (0.7 to 6.7) |
| Additional serotypes - serotype 3 | 92.1 (86.5 to 95.8) | 7.5 (3.8 to 13.0) |
| Additional serotypes - serotype 5 | 100.0 (97.6 to 100.0) | 72.1 (63.9 to 79.4) |
| Additional serotypes - serotype 6A | 100.0 (97.6 to 100.0) | 92.1 (86.5 to 95.8) |
| Additional serotypes - serotype 7F | 100.0 (97.6 to 100.0) | 4.2 (1.5 to 8.8) |
| Additional serotypes - serotype 19A | 100.0 (97.6 to 100.0) | 100.0 (97.6 to 100.0) |
Percentage of participants achieving predefined antibody threshold ≥5 EU/mL along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| PT ≥5 EU/mL | 50.7 (42.4 to 58.9) | 49.3 (41.1 to 57.6) |
| FHA ≥5 EU/mL | 91.4 (85.8 to 95.4) | 88.8 (82.7 to 93.3) |
| PRN ≥5 EU/mL | 99.3 (96.4 to 100.0) | 98.7 (95.3 to 99.8) |
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Tenderness: Any | 60.0 | 59.4 |
| Tenderness: Significant | 14.0 | 12.8 |
| Swelling: Any | 13.9 | 15.0 |
| Swelling: Mild | 10.3 | 13.6 |
| Swelling: Moderate | 5.9 | 1.4 |
| Swelling: Severe | 0.0 | 0.0 |
| Redness: Any | 10.3 | 13.4 |
| Redness: Mild | 8.8 | 11.4 |
| Redness: Moderate | 2.9 | 2.1 |
| Redness: Severe | 0.0 | 0.0 |
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Tenderness: Any | 53.3 | 53.8 |
| Tenderness: Significant | 9.4 | 11.9 |
| Swelling: Any | 12.1 | 13.8 |
| Swelling: Mild | 10.5 | 10.0 |
| Swelling: Moderate | 2.4 | 3.9 |
| Swelling: Severe | 0.0 | 0.0 |
| Redness: Any | 9.3 | 12.4 |
| Redness: Mild | 9.3 | 11.6 |
| Redness: Moderate | 0.0 | 1.6 |
| Redness: Severe | 0.0 | 0.0 |
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Tenderness: Any | 48.1 | 47.4 |
| Tenderness: Significant | 10.9 | 8.8 |
| Swelling: Any | 14.6 | 9.7 |
| Swelling: Mild | 12.2 | 9.7 |
| Swelling: Moderate | 4.2 | 0.9 |
| Swelling: Severe | 0.0 | 0.0 |
| Redness: Any | 10.7 | 14.0 |
| Redness: Mild | 10.7 | 13.3 |
| Redness: Moderate | 0.8 | 0.9 |
| Redness: Severe | 0.0 | 0.0 |
Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Tenderness: Any | 64.3 | 53.2 |
| Tenderness: Significant | 18.3 | 13.3 |
| Swelling: Any | 11.5 | 10.5 |
| Swelling: Mild | 8.1 | 8.7 |
| Swelling: Moderate | 5.3 | 3.9 |
| Swelling: Severe | 0.0 | 0.0 |
| Redness: Any | 13.3 | 8.7 |
| Redness: Mild | 12.4 | 7.8 |
| Redness: Moderate | 0.9 | 1.0 |
| Redness: Severe | 0.0 | 0.0 |
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Fever ≥38 but ≤39 degrees C | 18.0 | 19.9 |
| Fever >39 but ≤40 degrees C | 0.0 | 0.7 |
| Fever >40 degrees C | 0.0 | 0.0 |
| Decreased appetite | 26.6 | 28.0 |
| Irritability | 80.3 | 77.9 |
| Increased sleep | 56.6 | 52.4 |
| Decreased sleep | 39.7 | 27.5 |
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Fever ≥38 but ≤39 degrees C | 23.8 | 23.0 |
| Fever >39 but ≤40 degrees C | 3.2 | 0.8 |
| Fever >40 degrees C | 0.0 | 0.0 |
| Decreased appetite | 33.8 | 29.6 |
| Irritability | 80.4 | 79.2 |
| Increased sleep | 32.8 | 38.7 |
| Decreased sleep | 25.8 | 36.0 |
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Fever ≥38 but ≤39 degrees C | 22.6 | 22.4 |
| Fever >39 but ≤40 degrees C | 4.2 | 3.5 |
| Fever >40 degrees C | 0.8 | 0.9 |
| Decreased appetite | 37.9 | 32.2 |
| Irritability | 76.9 | 71.2 |
| Increased sleep | 35.7 | 36.9 |
| Decreased sleep | 27.6 | 34.1 |
Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC | 7vPnC |
|---|---|---|
| Fever ≥38 but ≤39 degrees C | 31.0 | 29.9 |
| Fever >39 but ≤40 degrees C | 1.8 | 3.0 |
| Fever >40 degrees C | 0.9 | 0.0 |
| Decreased appetite | 33.3 | 39.0 |
| Irritability | 67.2 | 68.8 |
| Increased sleep | 30.8 | 24.1 |
| Decreased sleep | 22.7 | 20.6 |
Collected over Baseline through 1 Month after last study vaccination (13 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1=2 months of age; Dose 2=4 months of age; Dose 3=6 months of age; Toddler Dose=12 months of age.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infant Series 13vPnC | — | 10/163 (6.1%) | 140/163 (85.9%) |
| Infant Series 7vPnC | — | 10/162 (6.2%) | 140/162 (86.4%) |
| After the Infant Series 13vPnC | — | 10/163 (6.1%) | 18/163 (11%) |
| After the Infant Series 7vPnC | — | 5/162 (3.1%) | 12/162 (7.4%) |
| Toddler Dose 13vPnC | — | 2/155 (1.3%) | 84/155 (54.2%) |
| Toddler Dose 7vPnC | — | 3/156 (1.9%) | 86/156 (55.1%) |
| Event | Infant Series 13vPnC | Infant Series 7vPnC | After the Infant Series 13vPnC | After the Infant Series 7vPnC | Toddler Dose 13vPnC | Toddler Dose 7vPnC |
|---|---|---|---|---|---|---|
| Hypotonic-hyporesponsive episodeNervous system disorders | 1/163 | 3/162 | 0/163 | 0/162 | 0/155 | 0/156 |
| BronchopneumoniaInfections and infestations | 0/163 | 0/162 | 2/163 | 2/162 | 0/155 | 2/156 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/163 | 0/162 | 2/163 | 1/162 | 1/155 | 2/156 |
| Urinary tract infectionInfections and infestations | 0/163 | 2/162 | 0/163 | 1/162 | 0/155 | 0/156 |
| PneumoniaInfections and infestations | 1/163 | 1/162 | 2/163 | 0/162 | 1/155 | 0/156 |
| LaryngitisInfections and infestations | 0/163 | 0/162 | 0/163 | 0/162 | 0/155 | 1/156 |
| DehydrationMetabolism and nutrition disorders | 0/163 | 1/162 | 1/163 | 0/162 | 0/155 | 1/156 |
| Congenital hydrocephalusCongenital, familial and genetic disorders | 0/163 | 0/162 | 0/163 | 1/162 | 0/155 | 0/156 |
| Inguinal herniaGastrointestinal disorders | 1/163 | 1/162 | 0/163 | 0/162 | 0/155 | 0/156 |
| IntussusceptionGastrointestinal disorders | 0/163 | 1/162 | 0/163 | 0/162 | 0/155 | 0/156 |
| Event | Infant Series 13vPnC | Infant Series 7vPnC | After the Infant Series 13vPnC | After the Infant Series 7vPnC | Toddler Dose 13vPnC | Toddler Dose 7vPnC |
|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 111/138 | 122/154 | — | — | — | — |
| IrritabilityGeneral disorders | 122/152 | 116/149 | — | — | 84/125 | 86/125 |
| IrritabilityGeneral disorders | 110/143 | 99/139 | — | — | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 87/145 | 92/155 | — | — | 81/126 | 67/126 |
| Increased sleepGeneral disorders | 81/143 | 77/147 | — | — | 36/117 | 26/108 |
| Tenderness (any)Skin and subcutaneous tissue disorders | 72/135 | 78/145 | — | — | — | — |
| Tenderness (any)Skin and subcutaneous tissue disorders | 63/131 | 63/133 | — | — | — | — |
| Decreased sleepGeneral disorders | 56/141 | 38/138 | — | — | 27/119 | 22/107 |
| Decreased appetiteGeneral disorders | 38/143 | 40/143 | — | — | 39/117 | 46/118 |
| Increased sleepGeneral disorders | 41/125 | 55/142 | — | — | — | — |
| Age Continuous(months) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Mean | 2.2 ± 0.2 | 2.2 ± 0.2 | 2.2 ± 0.2 |
| Sex: Female, Male(Participants) | 13vPnC | 7vPnC | Total |
|---|---|---|---|
| Female | 89 | 76 | 165 |
| Male | 74 | 86 | 160 |
The record gives a start of Apr 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →